Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.
about
Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell TransplantationInterleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.Advances in graft-versus-host disease biology and therapy.CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.Targeting the interleukin-6/Jak/stat pathway in human malignanciesAdvances in understanding the pathogenesis of graft-versus-host disease.JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.IFNγR signaling mediates alloreactive T-cell trafficking and GVHDSerum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity.Role of STAT3 in regulatory T lymphocyte plasticity during acute graft-vs.-host-diseaseHuman Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Next generation treatment of acute graft-versus-host disease.T-cell plasticity in inflammatory skin diseases--the good, the bad, and the chameleons.NLRC5 mediates cytokine secretion in RAW264.7 macrophages and modulated by the JAK2/STAT3 pathway.Identification of key genes implicated in the suppressive function of human FOXP3+CD25+CD4+ regulatory T cells through the analysis of time‑series data.Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.Therapeutic effects of STAT3 inhibition by nifuroxazide on murine acute graft graft-vs.-host disease: Old drug, new use.New and emerging therapies for acute and chronic graft versus host disease.The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials.Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.Immune Regulation in Hematopoietic Cell Transplantation
P2860
Q26752528-D14C09A7-99BB-4B37-BCDD-BD348109F1CAQ33774610-71E49B85-85E0-4172-9695-7083A2047005Q34031916-03668EED-750F-47FC-BE40-5E3B3A4C9DA6Q35207094-F9744BD5-0B20-4BAD-B371-502FD3FB2C6BQ35553632-D15DA5EE-1598-427B-A734-24E3EE547F79Q35925127-3E70914B-3707-4D7A-B68D-CAEA000D2C65Q35971439-CED8EA87-4038-40BA-9D49-D136B9A283D9Q35987345-CED43E0A-21B3-49B1-8A78-B522727F01AEQ36395621-DFBCBDC4-40C0-4010-B861-F2D5209C07A0Q36755491-F61DE0CD-6225-4686-BD7B-03FA6833A80AQ36905580-C917AA3B-C547-4BA2-8C7E-AED5B08F071BQ36980277-A79801DC-B68B-4811-9392-DC3F3154C694Q37496786-71EB2FCD-1D71-421F-B57E-14985431C6D2Q37529686-E269D584-B4E4-4294-AA56-696B856156D1Q37679267-1A27A7C8-63CE-4E8D-A27E-7BD16BA40A04Q38202009-29946A1B-9466-4B74-AB1D-A404298631A1Q38202155-DF544127-580E-4FC6-AC8E-202A321F8243Q38221028-937D7A81-56CD-4FB1-85BC-E940406A2DB2Q38522520-2B71C681-060B-4110-9225-442FA0F1CF3AQ39032558-6C3FE906-AFAD-4BA0-A05D-2CF6070295BAQ47235478-209DF221-47BF-4124-96A6-FA00617131D4Q48139357-22E07D9D-8353-43A6-A7D6-2AE2D1A8A769Q49222418-179B61C8-94BD-4C21-BDA1-59A3911E0F50Q49238507-4441F1B1-80AD-4582-AB00-186F8C627C90Q49384876-ECE32553-AC50-45AE-A0EB-904010E9D365Q49679320-BBD4646B-B7D8-47B2-ADF0-7CB081B9752BQ50115590-7F75062F-5484-45A4-9F81-2D846AB46F72Q52927960-373C9F39-6887-4D08-934B-52DE79BF04F8Q54186062-66AF0F31-A332-4302-9036-466A6348F7EFQ58415034-A24EDA9F-EAEF-48BD-ADA4-F9247FAF7C05
P2860
Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Janus kinase-2 inhibition indu ...... es immunity to recall antigen.
@ast
Janus kinase-2 inhibition indu ...... es immunity to recall antigen.
@en
type
label
Janus kinase-2 inhibition indu ...... es immunity to recall antigen.
@ast
Janus kinase-2 inhibition indu ...... es immunity to recall antigen.
@en
prefLabel
Janus kinase-2 inhibition indu ...... es immunity to recall antigen.
@ast
Janus kinase-2 inhibition indu ...... es immunity to recall antigen.
@en
P2093
P2860
P1433
P1476
Janus kinase-2 inhibition indu ...... es immunity to recall antigen.
@en
P2093
Brian C Betts
Erin T St Angelo
Glenn Heller
James W Young
Omar Abdel-Wahab
Priya Koppikar
Ross L Levine
Shane A Curran
P2860
P304
P356
10.1182/BLOOD-2011-06-363408
P407
P577
2011-09-13T00:00:00Z